Thus, patients with GH ≤6 ng/ml were 21.3 times more likely to respond to SRL than those with GH >6 ng/ml, adjusted by (basal ULN_IGF-1, gender, maximum tumor diameter, and BMI). The gene discussed is GH1; the disease is neoplasm.